• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Senzime

4.34 SEK

-1.59 %

Less than 1K followers

SEZI

NASDAQ Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-1.59 %
-5.03 %
0.00 %
-19.63 %
-18.88 %
-15.23 %
+44.67 %
-80.62 %
-26.87 %

Senzime operates in the medical technology industry and focuses on the development and manufacture of systems for monitoring and diagnostics in healthcare. The portfolio includes systems used to automate and measure the substances glucose and lactate in blood and tissues. The company's products are aimed at healthcare institutions and physicians. The operations are global. Senzime was founded in 1999 and is headquartered in Uppsala, Sweden.

Read more
Market cap
682.31M SEK
Turnover
91.12K SEK
Revenue
104.02M
EBIT %
-117.84 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
16/7
2026

Interim report Q2'26

29/10
2026

Interim report Q3'26

Press release6/5/2026, 8:00 AM

Senzime presenterar utökade TetraGraph-funktioner genom lanseringen av TetraAnalytics på Euroanaesthesia 2026

Senzime
Press release6/5/2026, 8:00 AM

Senzime to Showcase Expanded TetraGraph Capabilities with Launch of TetraAnalytics at Euroanaesthesia 2026

Senzime
Press release6/3/2026, 9:45 AM

Senzime stärker sin position inom barnanestesi genom att teckna ytterligare sjukhusavtal och lyfta fram positiv utfallsdata

Senzime

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release6/3/2026, 9:45 AM

Senzime strengthens position in pediatric anesthesia by securing another hospital contract and highlighting positive outcome data

Senzime
Press release6/1/2026, 9:00 AM

Senzime stärker erbjudandet inom hållbar anestesi med lansering av ny EMG-sensor

Senzime
Press release6/1/2026, 9:00 AM

Senzime Advances Sustainable Anesthesia Monitoring with Launch of New EMG Sensor

Senzime
Press release5/27/2026, 9:15 AM

Senzime erhåller FDA 510(k)-godkännande för utökade funktioner i TetraGraph-systemet

Senzime
Press release5/27/2026, 9:15 AM

From science to practice: Senzime obtains FDA 510(k) clearance for enhanced TetraGraph system

Senzime
Regulatory press release5/19/2026, 3:45 PM

Kommuniké från årsstämma i Senzime AB (publ)

Senzime
Regulatory press release5/19/2026, 3:45 PM

BULLETIN FROM ANNUAL GENERAL MEETING IN SENZIME AB (PUBL)

Senzime
Press release4/30/2026, 7:52 AM

Analyst Group: Analyst Group intervjuar Senzimes VD Philip Siberg

Senzime
Press release4/29/2026, 12:15 PM

Senzime förstärker den amerikanska verksamheten och ledningsgruppen

Senzime
Press release4/29/2026, 12:15 PM

Senzime strengthens U.S. operations with new leadership appointments

Senzime
Press release4/24/2026, 11:30 AM

Senzimes TetraGraph-system upphandlat i tre ledande GPO-avtal i USA

Senzime
Press release4/24/2026, 11:30 AM

Senzime’s TetraGraph System Contracted on Three Leading GPO Agreements in the US

Senzime
Regulatory press release4/24/2026, 10:00 AM

Senzime publishes annual and sustainability report for 2025

Senzime
Regulatory press release4/24/2026, 10:00 AM

Senzime publicerar års- och hållbarhetsredovisning för 2025

Senzime
Press release4/23/2026, 7:34 AM

Redeye: Senzime (Q1 Review): Temporary growth dip, with Q2 recovery expected

Senzime
Regulatory press release4/22/2026, 6:00 AM

Delårsrapport för Q1 2026: Stärkta marginaler och förbättrat kassaflöde trots temporärt hack i tillväxtkurvan. Årets målsättningar står fast.

Senzime
Regulatory press release4/22/2026, 6:00 AM

Margins strengthened and cash flow improved despite a temporary dip in the growth trajectory. Full-year targets remain on track.

Senzime